At a glance
ClinicalIndex Comparison Record- ✓Chronic HCV infection documented in a prior Gilead-sponsored HCV treatment study
- ✓Age 18 years or older
- ✓Did not achieve sustained virologic response (SVR) in a prior Gilead-sponsored HCV treatment study
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
In Brief
A Phase 3 clinical trial evaluating SOF/VEL/VOX for Hepatitis C Virus Infection. Completed, enrolled 31 participants across 27 sites in 7 countries.
Detailed Summary
The primary objectives of this study are to determine the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection with or without cirrhosis, who did not achieve sustained viral response (SVR) after receiving prior treatment in a Gilead-sponsored HCV treatment study of direct-acting antiviral (DAA)-containing regimens.
Study Details
Timeline
Interventions
400/100/100 mg FDC tablet administered orally once daily with food